BIT ! See latest Ann just out to quote.Scientists demonstrated...

BIT ! See latest Ann just out to quote.

Scientists demonstrated that Biotron’s p7 inhibitor,

BIT225, is active against HCV genotypes 1, 2, 4,

5 and 6.

Biotron has previously demonstrated that BIT225 is active

against genotypes 1 and 3 but clinical

trials have not yet extended to patients infected with

other strains of the virus.

Managing Director Dr Michelle Miller said that these latest results suggest Biotron’s compound has
pan-genotype activity.